DaVita HealthCare: Q3 Earnings Snapshot
DaVita HealthCare Partners Inc. (DVA) reported Q3 net income of $222.9M, or $3.40 per share, with adjusted EPS of $3.82. Revenue was $3.58B. The company expects full-year EPS of $14.30 to $15.20.
How this was made
The 30-second read
Why it matters
This is a direct earnings-and-guidance update that can change forward estimates and valuation multiples for DVA and influence sentiment across the dialysis care space.
Market read
Numeric EPS and revenue prints plus a full-year EPS range make this a tradable earnings update for DVA, with the key question being how it compares to consensus.
What to watch
Traders will likely weight cash flow, patient mix, and any commentary on utilization or reimbursement, none of which are included in this snapshot.
Background
AP/Zacks-generated earnings snapshot for DaVita’s third quarter, including reported and adjusted EPS, revenue, and full-year EPS guidance.
Ticker impact
DaVita reported Q3 net income of $222.9 million, EPS $3.40 (adjusted $3.82), revenue $3.58B, and guided full-year EPS to $14.30-$15.20.
Likely two-way reaction depending on whether the reported EPS and the $14.30-$15.20 guidance land above or below Street expectations.
The article provides both the quarter’s reported/adjusted EPS and a numeric full-year range, which are the primary inputs for earnings-model updates and valuation changes.
Market effects
Dialysis peers may see read-across on demand stability and reimbursement sensitivity given DaVita’s guidance range.
Limited, as the disclosure is company-specific rather than a broad US healthcare policy signal.
Low, since the event is a US-listed healthcare provider earnings release.
Counterpoint
Even with guidance, the stock reaction may be muted if investors focus more on reimbursement/regulatory headlines than on near-term EPS ranges.
Key entities
- companyDaVita HealthCare Partners Inc.
Kidney dialysis provider reporting Q3 results and issuing full-year EPS guidance.
